AIM ImmunoTech Inc. Common Stock AIM 深 滬
等待開盤 09-08 09:30:00 美东时间
0.2276
-0.006
-2.61%
華盛通- 最 高0.24
- 今 開0.2329
- 成交量 931.92万股
- 最 低 0.2266
- 昨 收 0.2337
- 總市值 808.16万
- 52周最高 2.977
- 市盈率 靜 --
- 換手率 26.25%
- 52周最低 0.1901
- 委 比 0.00%
- 總股本 3550.80万
- 歷史最高 20.3297
- 量 比 0.24
- 振 幅 5.73%
- 歷史最低 0.1901
- 每 手 1
- 風險率 0.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
AIM ImmunoTech Inc. (NYSE American: AIM) announced its participation in the Virtual Investor "Why Now" on-demand conference. CEO Thomas Equels presented the Company's investment thesis, emphasizing the pivotal moment for AIM. The presentation highlighted progress in the Phase 2 DURIPANC clinical trial for Ampligen® in metastatic pancreatic cancer, including successful enrollment completion ahead of schedule, dosing of the final patient, and antic...
08-27 13:01
美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $7
Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $9 to $7.
08-20 18:01
AIM ImmunoTech CEO Urges Biodefense Military Integration
AIM ImmunoTech ( ($AIM) ) has provided an announcement. On August 11, 2026, AIM...
08-11 21:00
AIM ImmunoTech GAAP EPS of -$0.43
AIM ImmunoTech press release (AIM): Q2 GAAP EPS of -$0.43. As of June 30, 2026, AIM reported $9.9 million in cash and cash equivalents, as compared to approximately $3.0 million as of December 31, 202...
08-10 20:40
AIM ImmunoTech Q2 EPS $(0.43) Misses $(0.18) Estimate, Sales $26.000K Up From $25.000K YoY
AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.18) by 138.89 percent. This is a 88.32 percent increase over losses of $(3.68) per share from the same period last year. The company reported $26.000 thousand in sales this qua...
08-10 20:38
AIM ImmunoTech Announces Final Subjects Receives Last Dose Of Ampligen Under Study Protocol In Phase 2 DURIPANC Clinical Study
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the final subject has received their last dose of Ampligen® (rintatolimod) under the study protocol, reaching this milestone ahead of schedule in the Phase 2 DURIPANC clinical trial evaluating Ampligen in combination with A...
08-03 20:41
AIM ImmunoTech Stockholders Approve Key Equity Proposals
AIM ImmunoTech ( ($AIM) ) just unveiled an update. On July 15, 2026, AIM Immuno...
07-17 17:18
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
AIM ImmunoTech Inc. announced the release of its latest CEO Corner segment, featuring CEO Thomas Equels discussing progress in pancreatic cancer treatment. Key points include successful patient enrollment and dosing in the DURIPANC Phase 2 study, encouraging interim results, favorable safety findings, Phase 3 planning, collaboration with AstraZeneca and Erasmus Medical Center, IP expansion, and Ampligen's potential in immunologically "cold" tumor...
07-07 13:03
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
AIM ImmunoTech Inc. announced the completion of enrollment in its Phase 2 DURIPANC trial combining Ampligen® with Imfinzi® for metastatic pancreatic cancer. The trial's primary endpoint, Clinical Benefit Rate, is expected to be analyzed by December 2026, with top-line results anticipated in Q1 2027. Secondary endpoints include overall survival, progression-free survival, and immune profiling. The company aims to use biomarker data to design a Pha...
06-18 13:01
